LOGIN
Muramyl tripeptide in chemotherapy improves overall osteosarcoma survival
August 2013
Muramyl tripeptide in chemotherapy improves overall osteosarcoma survival
Study Type:Therapy
OE Level Evidence:2
Journal Level of Evidence:N/A
Osteosarcoma: the addition of muramyl tripeptide to chemotherapy improves overall survival--a report from the Children's Oncology Group
J Clin Oncol. 2008 Feb 1;26(4):633-8. doi: 10.1200/JCO.2008.14.0095Did you know you're eligible to earn 0.5 CME credits for reading this report? Click Here
OE EXCLUSIVE
Dr. Paul A. Meyers discusses the addition of muramyl tripeptide to chemotherapy in the treatment of Osteosarcoma.
Synopsis
662 osteosarcoma patients without detectable metastatic disease were either randomized to three drug (cisplatin, doxorubicin, methotrexate) or four drug chemotherapy (cisplatin, doxorubicin, methotrexate, and ifosfamide). A further comparison was conducted on the effects of the addition muramyl tri-peptide (MTP) to both chemotherapy regimens. Four- and six-year evaluations of event free survival (...
To view the full content, login to your account,
or start your 30-day FREE Trial today.
FREE TRIAL
LOGIN
Forgot Password?
Explore some of our unlocked ACE Reports below!
Learn about our AI Driven
High Impact Search Feature
The OE High Impact metric uses AI to determine the impact a study will have by considering the content of the article itself. Built using the latest advances of natural language processing techniques. OE High Impact predicts an article’s future number of citations than impact factor alone.
Continue
Join the Conversation
Please Login or Join to leave comments.